A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2015
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors ARIAD Pharmaceuticals; Merck & Co
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2010 Merck and Co added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.
- 10 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.